*For medical professionals for reference
Gathering the seventh expo, the "Healthy China 2030" is built.
On November 5, 2024, the seventh China International Import Expo was grandly opened in the Shanghai National Convention and Exhibition Center.As one of the worlds largest import and export expo, the Expo has become an important platform for global cooperation and exchanges, showing the determination and action of mutual benefit and win -win and common prosperity of China.This years enlightenment focuses on the theme of "New Era, Sharing the Future", attracting exhibitors from more than 150 countries and regions around the world, covering many key areas such as science and technology, medical care, energy, and consumer goods.Many international companies have taken this opportunity to cooperate in more in -depth cooperation with the Chinese market to promote the global flow of technology and innovation, especially in emerging fields such as smart medical care, green development and digital economy.
This event coincides with "Global Lung Cancer Follow Month".The aimal activity of the series aims to improve the publics awareness of lung cancer, promote the development and application of innovative drugs, and improve the benefits of patients with lung cancer.
Zhongzhi Chengcheng
Write the innovation and transcendence of the new era
During the meeting, the " patients disease management jointly sponsored by the Beijing Heesco Clinical Oncology Research Foundation and the Education Expert Committee of the Patient Education Expert Committee of the Patient Education Expert Committee of the Patient Education Expert Committee of BeijingGuidelines (patient version) "(hereinafter referred to as" Guide ") held a project launching ceremony.The guidelines aims to provide a comprehensive content of covering diagnosis, treatment, adverse reactions, and daily life guidance from the perspective of the patient, and help patients and family members to better cope with multiple challenges in the process of disease.Subsequently, Alk -positive non -small cell lung cancer (NSCLC) "clinical healing" project initiated by the China Medical Care International Exchange Promotion Association also signed a memorandum of cooperation.This project is committed to helping clinicians and the public better understand the treatment status of Chinese ALK -positive NSCLC patients and the high -quality long survival benefits brought by innovative targeting therapy for patients, and further promote "clinical healing" to become the treatment goal of advanced lung cancer.Essence
Figure 1: "Guide to Management Guide for Disease Management (Patient Edition) of non-small cell lung cancer patients".-IMG#1->
Figure 2: China ALK-positive NSCLC "Clinical Healing" Project Cooperation Memorandum Signing Guest Ahabilities
Pfizer China ChinaMs. Wang Yu, deputy president of the district and general manager of the tumor division said during the meeting that this year is the 175th anniversary of Pfizers founding, and it is also the 35th anniversary of Pfizers rooting in China.Pfizer puts forward a new vision of Outdo Cancer worldwide, hoping to further surpass the drug itself on the basis of breakthrough innovation.accomplish.With the opening of the Expo, the stage of openness, tolerance, and opportunities, Pfizer will also explore more cross -border attempts and cooperation, gather more forces for anti -cancer, inject more humanistic care for scientific innovation, open a new new for tumor diagnosis and treatmentFuture imagination!
Patient version "Guide"
Help patients with lung cancer better self -management
In recent years, my countrys lung cancer treatment field has made many progress, and the treatment methods have become increasingly diverse.Especially in the treatment of NSCLC, the development of targeted therapy and immunotherapy has continuously extended the patients non -progressive survival (PFS). In this context, the management model of lung cancer has gradually changed to "slow disease", and the needs of patients needsIt also shifted from a single survival dimension to a comprehensive improvement of the quality of life.In order to meet this needs and help patients better grasp the scientific knowledge management knowledge, the patient version of the "Guidelines" led by the Beijing Hineco Clinical Oncology Research Foundation and the NSCLC Special Committee and the NSCLC Specialty Committeeborn.
At the event site, CSCO executive director, chairman, Professor Wang Biyun, Secretary General of the CSCO Education Expert Committee, Ms. Jin Ping, the founder of "Dance with Cancer", and Vice President of Pfizer China and General Manager of the Cancer Division, Ms. Wang Yu.Guidelines how to help promote lung cancer further "slow disease" management.
Figure 3: Listen to your voice: How to promote NSCLC further "slow disease" management round table forum
Professor Zhou Cun emphasized that the third-generation Alk-TKI application extend the median PFS of ALK-positive NSCLC patients to more than 5 years. The treatment of lung cancer is no longer limited to simple disease controlInstead, it has entered the "humanistic" stage centered on patients.In this regard, the patients version of the "Guide" relies on the CSCO authoritative platform, and is striving to simplify and popularize the complex medical knowledge to help patients realize self -management while improving the quality of survival and overall living standards.
Professor Wang Biyun pointed out that the channels for obtaining information related to the disease are not good, and tumor patients and family members sometimes fall into misunderstandings, and may even delay treatment.The launch of the patients version of the "Guide" helps to build a bridge between doctors and patients, help patients to see the sun and open the direction in the complicated information torrent, so that they can get more substantial benefits in treatment.
Ms. Jin Ping and Ms. Wang Yu expressed their opinions from the perspective of patient organization and enterprise. Ms. Jin Ping said that the patient version of the "Guide" will systematically list the entire process of NSCLC from diagnosis to treatment, explain the adverse reactions and its response strategies that may occur in the treatment, and add psychological support and in particularThe content of life management allows patients to fully master disease management skills and help patients regain their confidence in anti -cancer. Ms. Wang Yu further emphasizes the role of enterprises in the management of lung cancer "slow disease" management, that is, through the promotion of precision treatment and the transmission of scientific anti -cancer knowledge to enhance patients health literacy and self -managementConsciousness ultimately help the realization of the "Healthy China 2030" goal.
In short, the writing of the patients version of the "Guide" combines the authority of the expert and the actual needs of the patient, and strives to provide patients with more comprehensive and systematic disease management tools, and improve its self.Management ability adds help to realize the real "high -quality long survival".It is reported that after the launch, the Guide will enter the compilation stage and is expected to be launched in September 2025. Please look forward to it.
Benefits
From "slow disease" to "clinical healing"
At the annual meeting of the American Clinical Oncology (ASCO), further follow -up data of CROWN research was announced.At 60.2 months, the median PFS of Lolatinib has not yet reached, and the 5 -year PFS rate is as high as 60%, which refreshed the longest PFS record for targeted single drugs in advanced physical tumors [1].According to the definition of the World Health Organization (WHO), a 5 -year total survival rate (OS) of more than 50%of diseases can be regarded as "chronic disease" [2].From the past "talking about cancer color changes" to todays "coexistence with cancer", Alk -positive NSCLC has entered the era of "slow disease".
Figure 4 Weekly Professor List
The exploration has never stopped, and "clinical cure"The outlook is the common hopes of the doctors and patients for many years.In this regard, Professor Professor Zhou Cun delivered a speech on how to promote the theme of Chinese ALK -positive NSCLC patients from "slow disease" to "clinical cure".He said that lung cancer, as one of the most common malignant tumors in the world, seriously threatens human life and health.However, with the advancement of modern medicine, the treatment of lung cancer has spanned the stage of chemotherapy and entered a new era of targeted therapy and immunotherapy.Under the blessing of these treatment methods, lung cancer has gradually transformed from the past to malignant tumors that have been heard in the past into "chronic diseases" that can be managed.
Despite this, the incidence and mortality rate of lung cancer in my country remains high, and more clinical research and therapeutic innovation for lung cancer is still needed.At the same time, lung cancer in different stages has different treatment strategies. It is mainly surgery in the early stage, and comprehensive treatment is required in the middle and late stages. In advanced lung cancer, due to the no longer applicable to surgical treatment, the role of systemic treatment is increasingly critical.With the development of the new Alk-TKI, the survival benefits of patients are constantly refreshed.The latest data newspaper, after the first line of ALK-positive NSCLC patients received the third-generation ALK-TKI treatment in the first line, the 5-year-free progress rate of disease-free can reach 60%."Towards clinical healing."
Behind these breakthroughs, it is the common efforts of scientific research and clinical clinical, and future innovation will also depend on the in -depth exploration of precision medicine and targeted drugs.It is expected that clinicians can join hands with enterprises, bringing the light of hope for more lung cancer patients, and moving towards the goal of "clinical healing".
Summary
"Healthy China 2030" Planning Outline states that by 2030, my country will be in China. The 5 -year survival rate of overall cancer increased by 15%.The realization of this beautiful vision not only depends on the continuous innovation of medical technology, but also requires the active participation of the whole society.The launch of the patient version of the "Guideline" and the launch of ALK -positive NSCLC "clinical cure" project fully demonstrate the strength of all parties in improving the health education of patients, the application of cutting -edge treatment methods, and helping the management of further slow diseaseization of advanced lung cancer.Unremitting efforts.In the future, driven by the breakthrough of scientific research, industry collaboration, and the improvement of patients self -management awareness, more patients with lung cancer will take the "boat" of modern medicine and lead to the other side of hope.
Wonderful information is waiting for you
References:
[1] solomon bj, et al. Lorlatinib Versus Crizotinib in Patients with Advanced Alk-POSITIVE NON-Small LUNG CANCER: 5-Year Outcomes FROM THE hase III CROWN Study.j Clin Oncol. 2024May 31: JCO2400581.
[2] http://oncology.thelancent.com, vol 7 march 2006.
* This articleIt is only used to provide scientific information to medical people, does not represent the viewpoint of this platform
